Luo Fangyuan, Huang Yu, Li Yilin, Zhao Xiaolan, Xie Yao, Zhang Qianwen, Mei Jie, Liu Xinghui
Department of Obstetrics and Gynecology, West China Second University Hospital of Sichuan University, Chengdu, China.
Department of Obstetrics and Gynecology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China.
Ann Transl Med. 2021 Oct;9(20):1601. doi: 10.21037/atm-21-4879.
This paper reviews the association between transforming growth factor-β (TGF-β) and its receptor and tumor, focusing on gynecological malignant tumors. we hope to provide more methods to help increase the potential of TGF-β signaling targeted treatment of specific cancers.
The occurrence of a malignant tumor is a complex process of multi-step, multi-gene regulation, and its progression is affected by various components of the tumor cells and/or tumor microenvironment. The occurrence of gynecological diseases not only affect women's health, but also bring some troubles to their normal life. Especially when gynecological malignant tumors occur, the situation is more serious, which will endanger the lives of patients. Due to differences in environmental and economic conditions, not all women have access to assistance and treatment specifically meeting their needs. TGF-β is a multi-potent growth factor that maintains homeostasis in mammals by inhibiting cell growth and promoting apoptosis . TGF-β signaling is fundamental to inflammatory disease and favors the emergence of tumors, and it also plays an important role in immunosuppression in the tumor microenvironment. In the early stages of the tumor, TGF-β acts as a tumor inhibitor, whereas in advanced tumors, mutations or deletion of the TGF-β signaling core component initiate neogenesis.
Literatures about TGF-β and gynecological malignant tumor were extensively reviewed to analyze and discuss.
We discussed the role of TGF-β signaling in different types of gynecological tumor cells, thus demonstrating that targeted TGF-β signaling may be an effective tumor treatment strategy.
本文综述转化生长因子-β(TGF-β)及其受体与肿瘤之间的关联,重点关注妇科恶性肿瘤。我们希望提供更多方法,以助力提高针对特定癌症的TGF-β信号通路靶向治疗的潜力。
恶性肿瘤的发生是一个多步骤、多基因调控的复杂过程,其进展受肿瘤细胞和/或肿瘤微环境的各种成分影响。妇科疾病的发生不仅影响女性健康,还给她们的正常生活带来一些困扰。尤其是妇科恶性肿瘤发生时,情况更为严重,会危及患者生命。由于环境和经济条件的差异,并非所有女性都能获得满足其特定需求的援助和治疗。TGF-β是一种多能生长因子,通过抑制细胞生长和促进细胞凋亡来维持哺乳动物体内的稳态。TGF-β信号通路是炎症性疾病的基础,有利于肿瘤的发生,并且在肿瘤微环境的免疫抑制中也发挥着重要作用。在肿瘤早期,TGF-β作为肿瘤抑制因子发挥作用,而在晚期肿瘤中,TGF-β信号通路核心成分的突变或缺失会引发肿瘤新生。
广泛查阅有关TGF-β与妇科恶性肿瘤的文献进行分析和讨论。
我们探讨了TGF-β信号通路在不同类型妇科肿瘤细胞中的作用,从而表明靶向TGF-β信号通路可能是一种有效的肿瘤治疗策略。